ReviewInternational ophthalmology2026
Mitochondrial insufficiencies and neuroprotection in glaucoma.
Review in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAntihypertensive management has long been the mainstay of treatment for glaucoma. Despite contemporary treatments, many patients still experience disease progression, with some ultimately losing vision. The purpose of this review is to demonstrate how derangements in mitochondrial biology underpin the pathophysiology of glaucoma, and to explore emerging therapeutic options.
methodsLiterature searches were performed using multiple databases, aiming to identify recent developments in the scientific knowledge surrounding mitochondrial biology and glaucoma. Key words used in the primary literature search included combinations of "glaucoma", "mitochondria", "oxidative stress", "metabolism", "inflammation", "transport" and "genetics". Additional database searches were performed to further explore specific details identified in the primary search.
resultsRecent research points to mitochondrial insufficiencies as a primary culprit in the pathophysiology of glaucoma. Dysfunction of mitochondria occurs in a multitude of ways, and is an integral component of neuroinflammation, metabolic compromise, and disruption of axonal transport. This in part results from accumulated genetic factors, leading to generation of superoxides that damage retinal ganglion cells resulting in neurodegeneration of the optic nerve. Defects in mitochondrial biology among a range of ocular cell types contribute to the progression of glaucoma. With this understanding, emerging treatments targeting mitochondria, including gene therapies, tunneling nanotubules, and pharmacotherapeutics which enhance mitochondrial function and reduce oxidative stress, are likely the future of glaucoma management.
conclusionBy targeting mitochondrial insufficiencies as a root cause of glaucoma in addition to managing intraocular pressure, this new approach offers hope for preventing vision loss and potentially curing glaucoma.
Indexed as
Identifiers
42401758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.